Literature DB >> 28275086

The autism "epidemic": Ethical, legal, and social issues in a developmental spectrum disorder.

William D Graf1, Geoffrey Miller2, Leon G Epstein2, Isabelle Rapin2.   

Abstract

Classic autism has gradually evolved into the concept of a larger "spectrum disorder." The rising prevalence of autism and autism spectrum disorder (autism/ASD) diagnoses can be largely attributed to broader diagnostic criteria, adoption of dimensional assessment strategies, increased awareness, linking of services to diagnosis, and the inclusion of milder neurodevelopmental differences bordering on normality. The spectrum disorder diagnosis raises numerous bioethical issues for individuals and society. Three groups of caregivers have important ethical, legal, and social obligations to individuals with autism/ASD: (1) families and advocates of individuals with autism/ASD; (2) health care and other professionals; and (3) governments. Each group may have different views of autism/ASD diagnostic criteria, screening, testing, and the effectiveness of various interventions. All see timely diagnosis as desirable, but earlier diagnosis may not be better, morally or practically. The growing practice of genetic testing in milder ASD raises ethical questions because of its uncertain scientific validity and limited clinical utility. Individuals with autism/ASD have various kinds of needs but all want acceptance and most deserve better accommodations. Governments struggle to provide a fair allocation of appropriate special education and supportive services. This article examines the evolving dimensions of the autism/ASD diagnosis, outlines certain bioethics principles related to its evaluation and management, reviews relevant laws and disability rights, and emphasizes the societal obligation to recognize neurodevelopmental variation and human neurodiversity. Future directions in the evaluation and care of autism/ASD should attempt to integrate the roles and responsibilities of all agents caring for each unique autistic individual.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Year:  2017        PMID: 28275086     DOI: 10.1212/WNL.0000000000003791

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  [The epidemiology of mental disorders in youth : A narrative review including Austrian data].

Authors:  Martin Fuchs; Andreas Karwautz
Journal:  Neuropsychiatr       Date:  2017-08-30

2.  National and State Trends in autistic Adult Supplemental Security Income Awardees: 2005-2019.

Authors:  Kristy A Anderson; Jeffrey Hemmeter; David Wittenburg; Julia Baller; Anne M Roux; Jessica E Rast; Paul T Shattuck
Journal:  J Autism Dev Disord       Date:  2021-08-18

Review 3.  Ethical dimensions of translational developmental neuroscience research in autism.

Authors:  Arianna Manzini; Emily J H Jones; Tony Charman; Mayada Elsabbagh; Mark H Johnson; Ilina Singh
Journal:  J Child Psychol Psychiatry       Date:  2021-08-18       Impact factor: 8.982

4.  Isabelle Rapin (1927-2017).

Authors:  Michelle A Dunn
Journal:  J Autism Dev Disord       Date:  2017-08

5.  Air pollution and Autism in Denmark.

Authors:  Beate Ritz; Zeyan Liew; Qi Yan; Xin Cui; Jasveer Virk; Matthias Ketzel; Ole Raaschou-Nielsen
Journal:  Environ Epidemiol       Date:  2018-12

Review 6.  State of the Field: Differentiating Intellectual Disability From Autism Spectrum Disorder.

Authors:  Audrey Thurm; Cristan Farmer; Emma Salzman; Catherine Lord; Somer Bishop
Journal:  Front Psychiatry       Date:  2019-07-30       Impact factor: 4.157

7.  Diagnosis despite clinical ambiguity: physicians' perspectives on the rise in Autism Spectrum disorder incidence.

Authors:  Michael Davidovitch; Dorit Shmueli; Ran Shmuel Rotem; Aviva Mimouni Bloch
Journal:  BMC Psychiatry       Date:  2021-03-12       Impact factor: 3.630

Review 8.  Autism Spectrum Disorder Diagnoses: A Comparison of Countries with Different Income Levels.

Authors:  Marilia B Matos; Tiago S Bara; Mara L Cordeiro
Journal:  Clin Epidemiol       Date:  2022-08-13       Impact factor: 5.814

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.